Assessing the quality of life in patients with cancer

Current Problems in Cancer

Volumn 24, Issue 2, 2000, Pages 58-92

  Williams, S D ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PATIENT; COGNITION; COPING BEHAVIOR; EMOTION; HEALTH BEHAVIOR; PATIENT SATISFACTION; PHYSICAL PERFORMANCE; QUALITY OF LIFE; REVIEW; SOCIAL INTERACTION; WELLBEING;

EID: 0034019546     PISSN: 01470272     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0147-0272(00)90009-6     Document Type: Review

References (123)

1. Campbell S, Whyte F. The quality of life of cancer patients participating in phase I clinical trials using SEIQoL-DW. J Adv Nurs 1999;30:335-43.
2. Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA 1994:272:619-26.
3. Glick HA, Shpall EJ, LeMaistre CF, et al. Empirical criteria for the selection of quality of life instruments for the evaluation of peripheral blood progenitor cell transplantation. Int J Technol Assess Health Care 1998;14:419-30.
4. Hunt SM. Cross-cultural issues in the use of quality of life measures in randomized controlled trials. In: Staquet MJ, Hays RD, Fayers PM, editors. Quality of life assessment in clinical trials. New York: Oxford University Press; 1998. p. 51-68.
5. King CR, Haberman M, Berry DL, et al. Quality of life and the cancer experience: the state-of-the-knowledge. Oncol Nurs Forum 1997;24:27-41.
6. Lara-Munoz C, Feinstein Alvan R. How should quality of life be measured? J Investig Med 1999;47:17-24.
7. Sharp LK, Knight SJ, Nadler R, et al. Quality of life in low-income patients with metastatic prostate cancer: divergent and convergent validity of three instruments. Qual Life Res 1999;8:461-70.
8. Stephens RJ, Hopwood P, Girling DJ. Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise. Br J Cancer 1999;79:538-44.
9. Varricchio CG, McCabe MS, Trimble E, Korn EL. Quality of life in clinical cancer trials: introduction. J Natl Cancer Inst Monogr 1996;20:vii-viii.
10. Wilson IB, Cleary P. Linking clinical variables with health-related quality of life. JAMA 1995;273:59-65.
11. Berzon RA. Understanding and using health-related quality of life instruments within clinical research studies. In: Staquet MJ, Hays RD, Fayers PM, editors. Quality of life assessment in clinical trials. New York: Oxford University Press; 1998. p. 3-15.
12. Cella DF. Measuring quality of life in palliative care. Semin Oncol 1995;22(2 suppl 3):73-81.
13. Cramer JA, Spilker B. Quality of life pharmacoeconomics: an introduction. Philadelphia: Lippincott-Raven; 1998.
14. Hurny C, Bernhard J, Coates A. Quality of life assessment in the international breast cancer study group: past, present, and future. Recent Results in Cancer Res 1998;152:390-5.
15. Moinpour CM. Measuring quality of life: an emerging science. Semin Oncol 1994;21(5 suppl 10):48-63.
16. Read JL. The new era of quality of life assessment. In: Walker SR, Rosser RM, editors. Quality of life assessment: key issues in the 1990s. Boston: Kluwer Academic Publishers; 1993. p. 3-10.
17. Tannock IF, Boyer M. Treating the patient, not just the cancer. N Engl J Med 1987;317:1534-5.
18. Bardelli D, Saracci R. Measuring the quality of life in cancer clinical trials: methods and impact of controlled therapeutic trials in cancer. IUCC Tech Rep Ser 1978;36:75-97.
19. Karnofsky DA, Abelmann WH, Craver LF, et al. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948;1:634.
20. Kornblith AB, Holland JC. Model for quality of life research form the cancer and leukemia group b: the telephone interview, conceptual approach to measurement, and theoretical framework. J Natl Cancer Inst 1996;20:55-62.
21. McCabe MS. A cooperative group report on quality of life research: lessons learned. J Natl Cancer Inst Monogr 1996;20:63-5.
22. Gotay CC. Trial-related quality of life: using quality of life assessment to distinguish among cancer therapies. J Natl Cancer Inst Monogr 1996;20:1-6.
23. Neymark N, Kiebert W, Torfs K, et al. Methodological and statistical issues of quality of life (QoL) and economic evaluation in cancer clinical trials: report of a workshop. Eur J Cancer 1998;34:1317-33.
24. Ruta DA, Garratt AM, Leng M, et al. A new approach to the measurement of quality of life: the patient-generated index. Med Care 1994;32:1109-26.
25. Parker SL, Tong T, Bolden S, et al. Cancer statistics. CA Cancer J Clin 1997;47:68.
26. Gotay CC, Muraoka MY. Quality of life in long-term survivors of adult-onset cancers. J Natl Cancer Inst 1998;90:656-67.
27. Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol 1990;8:1777-81.
28. Schipper J, Clinch J, McMurray A, et al. Measuring the quality of life of cancer patients: the functional living index-cancer: development and validation. J Clin Oncol 1984;2:472-83.
29. Cella DF, Tulsky DS. Quality of life in cancer: definition, purpose, and method of measurement. Cancer Invest 1993;11:327-36.
30. Jenney MEM. Theoretical issues pertinent to measurement of quality of life. Med Pediatr Oncol Suppl 1998;1:41-5.
31. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993;118:622-9.
32. Beitz J, Gnecco C, Justice R. Quality of life end points in cancer clinical trials: the US food and drug administration perspective. J Natl Cancer Inst Monogr 1996;20:7-9.
33. Ganz PA, Rowland JH, Desmond K, et al. Life after breast cancer: understanding women's health-related quality of life and sexual functioning. J Clin Oncol 1998;16:501-14.
34. McClellan WM, Anson C, Birkeli K, et al. Functional status and quality of life: predictors of early mortality among patients entering treatment for end stage renal disease. J Clin Epidemiol 1991;44:83-9.
35. Bleehen NM, Girling DJ, Machin D, et al. A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC) II: quality of life. Br J Cancer 1993;68:1157-66.
36. de Haes JCJM, Olschewski M, Quality of life assessment in a cross-cultural context: use of a rotterdam sympton checklist in a multinational randomised trial comparing CMF and Zoladex (Goserlin) treatment in early breast cancer. Ann Oncol 1998;9:745-50.
37. Detmar SB, Aaronson NK. Quality of life assessment in daily clinical oncology practice: a feasibility study. Eur J Cancer 1998;34:1181-6.
38. Litwin MS, Hays RD, Fink A, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995;273:129-35.
39. Osoba D, Burchmore M. Health-related quality of life in women with metastatic breast cancer treated with trastuzumab (Herceptin). Semin Oncol 1999;4:84-8.
40. Potosky AL, Harlan LC, Stanford JL, et al. Prostate cancer practice patterns and quality of life: the prostate cancer outcomes study. J Natl Cancer Inst 1999;91:1719-24.
41. Watkins-Bruner D, Scott C, Lawton C, et al. RTOG's first quality of life study - RTOG 90-20: a phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer. Intl J Radiat Oncol Biol Phys 1995;33:901-6.
42. Selby P. Measuring the quality of life of patients with cancer. In: Walker SR, Rosser RM, editors. Quality of life assessment: key issues in the 1990s. Boston: Kluwer Academic Publishers; 1993. p. 235-67.
43. Cleary PD, Greenfield S, McNeil BJ. Assessing quality of life after surgery. Control Clin Trials 1991;12:189S-203S.
44. Sugarbaker PH, Barofsky I, Rosenberg SA, et al. Quality of life assessment of patients in extremity sarcoma clinical trials. Surgery 1982;91:17-23.
45. Diener E. Subjective well-being. Psychol Bull 1984;95:542-75.
46. Testa MA, Simonson DC. Assessment of quality-of-life outcomes. New Engl J Med 1996;334:835-40.
47. Cella DF, Bonomi A. Measuring quality of life: 1995 update. Oncology (Huntingt) 1995; 9(11 suppl):47-60.
48. Andersen BL. Surviving cancer. Cancer 1994;74(4 suppl):1484-95.
49. Cella DF. Quality of life outcomes: measurement and validation. Oncology (Huntingt) 1996;10(11 suppl):233-46.
50. Coates A, Gebski V, Stat M, et al. Improving the quality of life during chemotherapy for advanced breast cancer. N Engl J Med 1987;317:1490-5.
51. Baum M, Priestman T, West RR, Jones EM. A comparison of subjective responsese in a trial comparing endocrine with cytotoxic treatment in advanced carcinoma of the breast. Eur J Cancer 1980;Suppl 1:223-6.
52. Kiebert GM, de Haes JCM, van de Velde CJH. The impact of breast-conserving treatment and mastectomy on the quality of life of early stage breast cancer patients: a review. J Clin Oncol 1991;9:1059-70.
53. Moyer A. Psychosocial outcomes of breast-conserving surgery versus mastectomy: a meta-analytic review. Health Psychol 1997;16:284-93.
54. Taylor SE. Adjustment to threatening events: a theory of cognitive adaptation. Am Psychol 1983;38:1161-73.
55. Cella DF, Tulsky DS, Gray G, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570-9.
56. Sprangers MAG, Cull A, Groenvold M, et al. The European Organization for Research and Treatment of Cancer approach to developing questionnaire modules: an update and overview. Qual Life Res 1998;7:291-300.
57. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76.
58. Mandelblatt JS, Eisenberg JM. Historical and methodological perspectives on cancer outcomes research. Oncology (Huntingt) 1995;9(11 suppl):23-32.
59. Grant M, Padilla GV, Ferrell BR, et al. Assessment of quality of life with a single instrument. Semin Oncol Nurs 1990;6:260-70.
60. Testa MA, Nackley JF. Methods for quality-of-life studies. Annu Rev Public Health 1994;15:535-59.
61. Litwin MS, Hays RD, Fink A, et al. The UCLA prostate cancer index: development, reliability, and validity of a health related quality of life measure. Med Care 1998;36:1002-12.
62. Patrick DL, Danis M, Southerland LI, et al. Quality of life following intensive care. J Gen Intern Med 1988;3:218-23.
63. Ormel J, Lindenberg S, Steverink N, et al. Quality of life and social production functions: a framework for understanding health effects. Soc Sci Med 1997;45:1051-63.
64. Spilker B. Introduction. In: Spilker B, editor. Quality of life assessments in clinical trials. New York: Raven Press; 1990. p. 3-9.
65. King CR, Ferrell BR, Grant M, et al. Nurses' perceptions of the meaning of quality of life for bone marrow transplant survivors. Cancer Nurs 1995;18:118-29.
66. Sprangers MA, Aaronson NK. The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease: a review. J Clin Epidemiol 1992;45:743-60.
67. Simon GE, Goldberg D, Tiemens BG, et al. Outcomes of recognized and unrecognized depression in an international primary care study. Gen Hosp Psychiatry 1999;21:97-105.
68. Hutchinson TA, Boyd NF, Feinstein AR. Scientific problems in clinical scales as demonstrated in the Karnofsky index of performance status. J Chronic Dis 1979;32:661-6.
69. Spitzer WO, Dobson AJ, Hall J, et al. Measuring the quality of life in cancer patients: a concise Q/L index for use by physicians. J Chronic Dis 1981;34:585-97.
70. Fries JF, Spitz PW. The hierarchy of patient outcomes. In: Spilker B, editor. Quality of life assessments in clinical trials. New York: Raven Press; 1990. p. 25-35.
71. Brenner MH, Curbow B, Legro MW. The proximal-distal continuum of multiple health outcome measures: The case of cataract surgery. Med Care 1995;33(suppl): AS236-44.
72. Brief AP, Butcher AH, George JM, et al. Integrating bottom-up and top-down theories of subjective well-being: the case of health. J Pers Soc Psychol 1993;64:646-53.
73. Andrews FM, Withey SB. Social indicators of well-being: America's perception of life quality. New York: Plenum; 1976.
74. Diener E, Emmons RA. The independence of positive and negative affect. J Pers Soc Psychol 1984;47:1105-17.
75. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36); I: conceptual framework and item selection. Med Care 1992;30:473-83.
76. Weinberger M, Oddone EZ, Samsa GP, et al. Are health-related quality of life measures affected by the mode of administration? J Clin Epidemiol 1996;49:135-40.
77. Detmar SB, Aaronson NK. Quality of life assessment in daily clinical oncology practice: a feasibility study. Eur J Cancer 1988;34:1181-6.
78. O'Hare AE, Aitken K, Eden OB. Computerized psychometry screening in longterm survivors of childhood acute lympholastic leukemia. Pediatr Hematol Oncol 1988;5:197-208.
79. Bullinger M. Indices versus profiles - advantages and disadvantages. In: Walker SR, Rosser RM, editors. Quality of life assessment: key issues in the 1990's. Boston: Kluwer Academic Publishers; 1993. p. 209-20.
80. Stockler MR, Osoba D, Corey P, et al. Convergent discriminitive, and predictive validity of the prostate cancer specific quality of life instrument (PROSQOLI): assessment and comparison with analogous scales from the EORTC QLQ-C30 and a trial-specific module. J Clin Epidemiol 1999;52:653-66.
81. Revicki DA, Leidy NK. Questionnaire scaling: models and issues. In: Staquet MJ, Hays RD, Payers PM, editors. Quality of life assessment in clinical trials. New York: Oxford University Press; 1998. p. 157-68.
82. Bergner M, Bobbitt RA, Carter WB, et al. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981;19:787-805.
83. Ferrans CE. Quality of life: conceptual issues. Semin Oncol Nurs 1990b;6:248-54.
84. Patrick DL, Erickson P. Assessing health-related quality of life for clinical decision-making. In: Walker SR, Rosser RM, editors. Quality of life assessment: key issues in the 1990s. Boston: Kluwer Academic Publishers; 1993. p. 11-63.
85. Kaplan RM. Profile versus utility based measures of outcome for clinical trials. In: Staquet MJ, Hays RD, Fayers PM, editors. Quality of life assessment in clinical trials. New York: Oxford University Press; 1998. p. 69-92.
86. Schag CA, Ganz PA, Heinrich RL, et al. Rehabilitation Evaluation System - short form (CARES-SF): a cancer specific rehabilitation and quality of life instrument. Cancer 1991;68:1406-13.
87. Cella D. Manual of the functional assessment of chronic illness therapy (FACIT) scales, version 4. Chicago: Evanston Northwestern Healthcare and Northwestern University; 1997.
88. Nunnally JC, Bernstein IH. Psychometric theory. 3rd ed. New York: McGraw-Hill; 1994.
89. Kidder LH, Judd CM, Smith ER. Research methods in social relations. New York: Holt, Rinehart & Winton; 1986.
90. Hays RD, Anderson RT, Revicki D. Assessing reliability and validity of measurement in clinical trials. In: Staquet MJ, Hays RD, Fayers PM, editors. Quality of life assessment in clinical trials. New York: Oxford University Press; 1998. p. 169-82.
91. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1957;3:297-334.
92. Andersen BL, Cyranowski JM. Women's sexual self-schema. J Pers Soc Psychol 1994;67:1079-100.
93. Bjerre BD, Johansen C, Steven K. Health-related quality of life after cystectomy: bladder substitution compared with ileal conduit diversion: a questionnaire survey. Br J Urol 1995;75:200-5.
94. Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures. Control Clin Trials 1991;12:142S-58S.
95. Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality of life scores. J Oncol 1998;16:139-44.
96. Froberg DG, Kane RL. Methodology for measuring health-state preferences-I: measurement strategies. J Clin Epidemiol 1989;42:345-54.
97. Feeny DH, Torrance GW. Incorporating utility-based quality of life assessment measures in clinical trials. Med Care 1989;27:S190-204.
98. Torrance GW. Measurement of health status utilities for economic appraisal: a review. J Health Econ 1986;5:1-30.
99. Nease RF, Kneeland T, O'Connor GT, et al. Variation in patient utilities of outcomes of the management of chronic stable angina. JAMA 1995;273:1185-90.
100. Tsevat J, Cook EF, Green ML, et al. Health values of the seriously ill. Ann Intern Med 1995;122:514-20.
101. Kaplan RM, Feeny D, Revicki DA. Methods for assessing relative importance in preference based outcome measures. Qual Life Res 1993;2:467-75.
102. Giesler RB, Ashton CM, Brody B, et al. Assessing the performance of utility techniques in the absence of a gold standard. Med Care 1999;37:580-8.
103. Furlong W, Feeny D, Torrance GW, et al. Guide to design and development of health-state utility instrumentation. Paper #90-9 in the Center for Health Economics and Policy Analysis Working Paper Series, McMaster University; 1990.
104. Lenert LA, Morss S, Goldstein MK, et al. Measurement of validity of utility elicitations performed by computerized interview. Med Care 1997;35:915-20.
105. Kaplan RM, Anderson JP, Ganiats TG. The quality of well-being scale: rationale for a single quality of life index. In: Walker SR, Rosser RM, editors. Quality of life assessment: key issues in the 1990s. Boston: Kluwer Academic Publishers; 1993. p. 65-94.
106. Schwarz CE, Laitin EA. Using decision theory in clinical research: applications of quality-adjusted life-years. In: Staquet MJ, Hays RD, Fayers PM, editors. Quality of life assessment in clinical trials. New York: Oxford University Press; 1998. p. 119-42.
107. Gelber RD, Goldhirsch A, Cavalli F. Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer: The International Breast Cancer Study Group. Ann Intern Med 1991;114:621-8.
108. Gelber RD, Bonetti M, Cole BF, et al. Quality of life assessment in the adjuvant setting: is it relevant? Recent Results Cancer Res 1998;152:373-89.
109. Rosendahl I, Kiebert GM, Curran D, et al. Quality-adjusted survival (Q-Twist) analysis of EORTC trial 30853: comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer. Prostate 1999;38:100-9.
110. Cowen ME, Miles BJ, Cahill DF, et al. The danger of applying group-level utilities in decision analyses of the treatment of localized prostate cancer in individual patients. Med Decis Making 1998;18:376-80.
111. Mulley AG Jr. Assessing patients' utilities - can the ends justify the means? Med Care 1989;27:S269-81.
112. Hornberger JC, Redelmeier DA, Petersen J. Variability among methods to assess patients' well-being and consequent effect on a cost-effectiveness analysis. J Clin Epidemiol 1992;45:505-12.
113. Read JL, Quinn RJ, Berwick DM, et al. Preferences for health outcomes: comparison of assessment methods. Med Decis Making 1984;4:315-29.
114. Deyo RA. Measuring the quality of life of patients with rheumatoid arthritis. In: Walker SR, Rosser RM, editors. Quality of life assessment: key issues in the 1990s. Boston: Kluwer Academic Publishers; 1993. p. 269-88.
115. Giesler RB, Williams SD. Opportunities and challenges: assessing quality of life in clinical trials. J Natl Cancer Inst 1998;90:1498-9.
116. Lydick E, Yawn B. Clinical interpretation of health-related quality of life data. In: Staquet MJ, Hays RD, Fayers PM, editors. Quality of life assessment in clinical trials: methods and practice. Oxford: Oxford University Press; 1998. p. 299-314.
117. Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:407-15.
118. Marder SR, Mintz J, Van Putten R, et al. Early prediction of relapse in schizophrenia: an application of receiver operating charactertistics (ROC) methods. Psychopharmacol Bull 1991:27:79-82.
119. Fairclough DL, Cella DF. Eastern cooperative oncology group (ECOG). J Natl Cancer Inst Monogr 1996;20:73-5.
120. Moinpour CM. Costs of quality of life research in southwest oncology group trials. J Natl Cancer Inst Monogr 1996;20:11-6.
121. Stead ML, Crocombe WD, Fallowfield LJ. Sexual activity questionnaires in clinical trials: acceptability to patients with gynaecological disorders. Br J Obstet Gynaecol 1999;106:50-4.
122. Ringdal K, Ringdal GI, Kaasa S, et al. Assessing the consistency of psychometric properties of the HRQoL scales within the EORTC QLQ-C30 across populations by means of the Mokken scaling model. Qual Life Res 1999;8:25-38.
123. Hays RD. Item response models. In: Staquet MJ, Hays RD, Fayers PM, editors. Quality of life assessment in clinical trials. New York: Oxford University Press; 1998. p. 183-90.